Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Buys Acrux Testosterone Drug
by Lisa M. Jarvis
March 22, 2010
| A version of this story appeared in
Volume 88, Issue 12
Eli Lilly & Co. will pay Australian drug delivery firm Acrux $50 million for access to Axiron, an underarm testosterone treatment being considered by FDA to treat men with a deficiency of the hormone. Acrux will get another $87 million if the drug is approved, and it will receive royalties and up to $195 million in sales-based milestones. According to the companies, up to 39% of men over 45 have levels of testosterone that are less than healthy, but only 10% of those affected get treatment. IMS Health says annual sales of testosterone gels in the U.S. total $760 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter